Johnson & Johnson (NYSE: JNJ) has successfully concluded its acquisition of Yellow Jersey, a division previously part of Numab Therapeutics, for a substantial $1.25 billion. This strategic move secures Johnson & Johnson the exclusive global rights to NM26, a pioneering bispecific antibody set to advance into Phase 2 trials for treating atopic dermatitis (AD). NM26 […]
In a significant development for the treatment of atopic dermatitis (AD), Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the U.S. Food and Drug Administration (FDA) approval of ZORYVE (roflumilast) cream, 0.15%, for patients aged six years and older. This approval marks a pivotal advancement in immuno-dermatology, offering a steroid-free, once-daily cream that targets mild to moderate […]
In a significant move to enhance its immunology offerings, Johnson & Johnson (NYSE: JNJ) has announced a definitive agreement to acquire a wholly-owned subsidiary of Numab Therapeutics, gaining global rights to an investigational bispecific antibody, NM26. The deal, valued at approximately $1.25 billion, is poised to transform treatment paradigms in atopic dermatitis (AD) and potentially […]
LEO Pharma, a leading Danish pharmaceutical company, has acquired global exclusive rights to the atopic dermatitis drug JW1601 from JW Pharmaceutical (JWP), in a significant deal valued at approximately KRW 450 billion ($402 million). This licensing agreement, however, excludes South Korea, where JWP will retain exclusive rights. Under the terms of the agreement, LEO Pharma […]
Dupixent (dupilumab), the co-developed eczema injection from pharma giants Sanofi and Regeneron Pharmaceuticals, has got the US FDA approval for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients.
Sanofi and Regeneron Pharmaceuticals have announced a significant advancement in dermatological care with the U.S. Food and Drug Administration (FDA) approving Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. This marks Dupixent as the first biologic medication approved for patients who have not responded adequately to traditional topical prescription treatments […]
The jointly developed eczema drug, Dupixent (dupilumab) from Sanofi and Regeneron Pharmaceuticals has succeeded in a pivotal phase 3 Atopic dermatitis clinical trial.
Sanofi and Regeneron Pharmaceuticals have achieved a significant milestone with their jointly developed eczema drug, Dupixent (dupilumab), meeting the primary endpoints in a year-long Phase 3 clinical trial for adults with uncontrolled moderate-to-severe atopic dermatitis (AD). Breakthrough in Atopic Dermatitis Treatment The CHRONOS trial, a critical phase 3 study, involved Dupixent administered alongside topical corticosteroids […]